DYNAVAX TECHNOLOGIES CORP (DVAX)
Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.
Address
2100 POWELL STREET
EMERYVILLE, CA 94608
Founded
1996
Number of Employees
408
Website
http://www.dynavax.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | $196 | - | - | - | - | - | - | - | - | $196 |
| Average Price | - | - | $4.62 | - | - | - | - | - | - | - | - | $4.62 |
| # Shares Purchased | - | - | 42,511 | - | - | - | - | - | - | - | - | 42,511 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | 138.1% | - | - | - | - | - | - | - | - | 138.1% |
| S&P 500 Return to Date | - | - | 168.6% | - | - | - | - | - | - | - | - | 168.6% |
| Excess Total Return | - | - | -30.5% | - | - | - | - | - | - | - | - | -30.5% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | 67% | - | - | - | - | - | - | - | - | 89% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at DVAX make a trade.
Creating a free account takes less than one minute